OBJECTIVE: The weight loss achieved during treatment with very-low-calorie diets (VLCD) varies between individuals. The aim of this study was to investigate whether interindividual variations in catecholamine-induced lipolysis are of importance for the rate of weight loss during VLCD. DESIGN: Prospective study. SUBJECTS: Twenty-eight obese, but otherwise healthy and drug-free women aged 20±57 y with BMI 33.3±47.5 kg/m 2 were investigated before entering a four week weight reduction program with a calorie-restricted diet. MEASUREMENTS: A subcutaneous adipose tissue biopsy was obtained from the abdominal area. Isolated fat cells were prepared and incubated in vitro with agents acting on lipolysis at de®ned steps in the lipolytic cascade. Glycerol release was measured and used as a lipolytic index. Following the biopsy, the subjects underwent a four week VLCD treatment. RESULTS: The decrease in body weight in the whole group ranged between 4.8 and 13.5 kg. Dietary compliance was ascertained by daily measurements of urine-ketones and regular interviews and was satisfactory in all subjects throughout the study. Based on percent body weight reduction, the material was divided into two equally sized groups, classi®ed as rapid or slow weight losers. The rapid weight losers were 10-fold more sensitive to the lipolytic effect of noradrenaline (P 0.04) and 10-fold less sensitive (P 0.002) to the antilipolytic effect induced by the a 2 -adrenoceptor agonist clonidine than the slow weight losers. In the whole material, weight loss was signi®cantly correlated (adjusted r 2 0.25) with a 2 -adrenoceptor sensitivity. CONCLUSION: Rapid weight loss during VLDC is associated with increased adipocyte lipolytic sensitivity to catecholamines due to decreased a 2 -adrenoceptor sensitivity, which in turn may promote lipid mobilization. It appears that variations in a 2 -adrenoceptor sensitivity in adipocytes may be predictive of weight loss during VLCD.
Introduction
Obesity is a major health problem in wealthy countries. Long-term dietary restriction with the use of very low-calorie diets (VLCDs) is a common therapy to induce weight loss in obese patients. 1 However, weight reduction during caloric restriction is not always successful and there is a considerable variation in weight loss between individuals. 2 Predictors of weight loss during VLCD are endogenous factors such as initial body weight, resting metabolic rate and grade of self-ef®cacy, and so-called treatment factors, including length of treatment, the absence or presence of social support and physical activity. 3 Managing treatment of obesity is highly dependent of the person's compliance and attendance to the program, but despite full compliance the response to dietary treatment may vary between subjects. Such variations could in theory be localized at the cellular level and involve adipocyte metabolism, since the major feature of obesity is excess lipid accumulation in fat cells.
During hypocaloric treatment a reduction in body weight is achieved mainly through a decrease in fat mass. Lipids are mobilized from fat cells via lipolysis; the hydrolysis of triglycerides to glycerol and free fatty acids. 4 This process is controlled by several hormones, among which catecholamines are the most important lipolytic ones in humans. They act via G-protein coupled adrenergic receptors and have a dual effect on lipolysis by stimulating via b 1 , b 2 and b 3 -adrenoceptors and inhibiting through a 2 -adrenoceptors. In human subcutaneous adipose tissue b 1 , b 2 and a 2 -adrenoceptors predominate, whereas the b 3 -adrenoceptor mostly is present in the visceral fat depots. 5, 6 Previous in vivo and in vitro studies have shown that the increased lipid mobilization from adipose tissue during fasting is mediated mainly by catecholamines via stimulation of b-adrenoceptors. 4, 7 In vitro studies on short-term starvation have demonstrated resistance to catecholamine-induced lipolysis as well as changes in the ability of insulin to suppress lipolysis. 5, 8 However, it has recently been shown that during long-term VLCD, b-and a 2 -adrenoceptor function is unchanged in subcutaneous fat cells. 9 It is, thus, possible that individual differences in adrenergic regulation of adipocyte lipolysis that are present already before VLCD could be of importance for variations in the rate of weight loss when this form of treatment is given to obese subjects.
In the present study, we have examined the possible role of catecholamine induced fat cell lipolytic activity in producing weight loss during VLCD treatment of obesity. Subcutaneous fat cells from the abdominal region were obtained from 28 obese women before entering a four week weight reduction program. The effects on lipolysis of catecholamines and selective adrenoceptor-and post-receptor acting drugs were examined and data were correlated to the rate of weight loss.
Material and methods
Twenty-eight obese, but otherwise healthy and drugfree women participated in the study. The body mass index (BMI) ranged from 33.3±47.5 kg/m 2 and the waist-hip ratio ranged from 0.86±1.02. The participants were sedentary or undertook moderate exercise not more than once a week. All had had stable body weight during at least six months preceding the study. Their age ranged from 20±57 y. Two women were postmenopausal. Women in fertile age were examined in the follicular phase of the menstrual cycle. All subjects had given their informed consent prior to entering the study. The study was approved by the ethic's committee of the Karolinska Institute.
The subjects were examined before entering a weight reduction program. They were investigated in the morning after an overnight fast. Height, body weight and waist-hip ratio were measured. First, after 15 min rest in the supine position, venous blood samples were obtained for analysis of glucose, lipids, glycerol and catecholamines by the hospital's routine chemistry laboratory and insulin by our own laboratory (using a commercial radioimmuno assay kit from Pharmacia, Uppsala, Sweden). Pulse and blood pressure were measured. Second, a subcutaneous fat biopsy, of about 2±3 g, was surgically removed under local anaesthesia from the paraumbilical region as described. 10 The subjects were then given a balanced liquid formula VLCD, administered ®ve times daily, a total of 400 kcal/d for four weeks. The diet kit (Nutrilette R, Nycomed, Oslo, Norway), consisted of 63% protein, 6% fat, 31% carbohydrate and was supplemented with essential vitamins and minerals. To ascertain compliance to the diet, the following procedure was followed. At the start of the treatment each participant was given 35 VLCD packages for one week's consumption. Throughout the study the subjects returned to the Obesity Unit every week and received another 35 VLCD packages. They were instructed to return any non-consumed VLCD packages every week. Furthermore, to ascertain compliance to the diet, each subject collected urine samples every morning at home in date-labelled tubes that were returned at the weekly visit. In these samples the urine-ketone content was analyzed using semi-quantitative reagent sticks (N-Labstix from Bayer Diagnostics). At the weekly visit the subjects participated in a one hour group meeting and for individual support a short meeting with a trained nurse at the Obesity Unit during which a dietary recall interview was performed.
Isolation of fat cells and lipolysis experiments
Isolated fat cells were prepared by incubation in collagenase buffer according to Rodbell. 11 Fat cell diameter, weight and volume as well as the number of fat cells incubated were determined as described. 12 The lipolysis assay has previously been described in detail. 12 Brie¯y, a diluted suspension of fat cells (about 5±10 000 cells/ml) was incubated in duplicate, with air as the gas phase, for 2 h at 37 C in Krebs± Ringer phosphate buffer (pH 7.4) supplemented with glucose (1 mg/ml), ascorbic acid (0.1 mg/ml) and bovine serum albumin (20 mg/ml) in the absence (basal) or presence of increasing concentrations of different lipolytic and antilipolytic agents. We used the non-selective, natural catecholamine, noradrenaline, which acts on all three b-adrenoceptor subtypes and the a 2 -adrenoceptor, the b 2 -adrenoceptor-selective agonist terbutaline and the b 1 -adrenoceptor-selective agonist dobutamine. Furthermore, the antilipolytic a 2 -adrenoceptor agonist clonidine, forskolin which stimulates adenylyl cyclase and the phosphodiesterase resistant cyclic AMP-analogue dibutyryl cyclic AMP (dcAMP), stimulating the protein kinase-hormone-sensitive lipase complex, were used.
In the experiments with clonidine, the incubation buffer was supplemented with adenosine deaminase (ADA, 1 U/ml) in order to eliminate all traces of adenosine, as this substance may interact with the antilipolytic effects that are mediated via the a 2 -adrenergic receptors. In the diluted fat cell suspension presently used, there is no in¯uence of traces of adenosine on the effect of agents that stimulate lipolysis as discussed. 12 After incubation, an aliquot of the medium was removed and glycerol (lipolytic index) was analyzed using a bioluminescence method. 13 All the agonists caused a dose-dependent increase or inhibition of glycerol release, reaching a plateau at the highest agonist concentrations. The sensitivity to agonist action was de®ned as the pD 2 value, namely the negative logarithm of the EC 50 value; the concentration of each agonist giving half maximum effect. The EC 50 values were determined by linear regression analysis after log-logit transformation of each individual dose-response curve. The responsiveness to the agonists was de®ned as the lipolytic rate at the maximum effective agonist concentration with the basal lipolysis rate subtracted. As regards clonidine, data were expressed as the degree of inhibition relative-to-basal. The lipolysis rates were related to the number of incubated cells and expressed per cell number.
Drugs and chemicals
Bovine serum albumin (fraction V, lot 63F-0748), clostridium histolyticum collagenase type I, forskolin, dibutyryl cAMP and glycerol kinase from E. Coli (G4509) were obtained from Sigma (St Louis, MO, USA). Noradrenaline and isoprenaline came from Ha Èssle (Mo Èlndal, Sweden), terbutaline from Draco (Lund, Sweden,), dobutamine from Lilly (Indianapolis, IN, USA) and clonidine from Boehringer Ingelheim (Rhein, FRG). ATP monitoring reagent containing ®re¯y luciferase was from LKB Wallac (Turku, Finland). All other chemicals were of the highest grade of purity commercially available. Collagenase and other ingredients in the incubation buffers were from the same batches throughout the study.
Statistical analysis
Data are presented as means AE standard error of the mean (s.e.). Data were compared using Student's unpaired t-test, linear or stepwise regression analysis.
Results
All 28 subjects participating in the study achieved a substantial body weight reduction of mean 8.9 AE 0.4 kg after four weeks of VLCD. However, the actual weight loss was markedly different between the subjects, the range being 4.8±13.5 kg in the whole group. No VLCD packages were returned by the subjects at the weekly meetings. Judging from these data and the results of the individual interviews, all subjects followed the prescribed dietary regime. The results of the daily urine sampling with subsequent analysis of urine-ketone content further indicated satisfactory compliance. In each case the urineketone concentration increased during the ®rst week and was thereafter stable at the maximum level.
On the basis of percent body weight lost during the four weeks of VLCD, the subjects were divided into two equally sized groups, classi®ed as either rapid or slow weight losers. Clinical data of the two groups (obtained before VLCD was initiated) are presented in Table 1 . The groups were almost identical as regards age, BMI and waist-hip ratio, and no signi®cant differences were seen in fat cell volume, blood pressure, plasma concentrations of glycerol, catecholamines, insulin or blood glucose before the VLCD program.
The rapid weight losers achieved 10.3 AE 0.5 kg reduction in body weight after four weeks of VLCD, as compared to 7.5 AE 0.5 kg in the slow weight losing group. The values were essentially the same if the two postmenopausal women were excluded. Figure 1 depicts the changes in body weight in the two groups, expressed as percentage of initial value. As demonstrated, the difference in weight loss between the two groups was apparent after one week on VLCD and remained throughout the whole period of hypocaloric treatment.
The lipolytic effects (with the basal value subtracted) at maximum effective concentrations of noradrenaline, isoprenaline, forskolin and dcAMP are Lipolysis and weight loss L Hellstro Èm et al shown in Table 2 . In this respect, no differences were found before VLCD between rapid and slow weight losers. Also the basal lipolysis rate, with or without the addition of ADA, as well as the maximum antilipolytic effect of clonidine was equal in both groups. Clonidine inhibited basal lipolysis rate by 82.4 AE 2.4% and by 84.6 AE 1.6% in the rapid and slow weight losers, respectively (P ns). Adrenoceptor sensitivity was determined with noradrenaline and with the adrenoceptor selective agents terbutaline, dobutamine and clonidine. The results of this evaluation, as calculated from individual dose response curves, are listed in Table 3 . The rapid weight losers were signi®cantly more sensitive to the lipolytic effect of noradrenaline and less sensitive to the antilipolytic effect of the a 2 -adrenoceptor agonist clonidine as compared to the slow weight losers. The pD 2 values for noradrenaline in the`rapid' and slow' group were about 8 and 7 log mol/l and for clonidine about 9 and 10 log mol/l, respectively. There were no signi®cant differences in the sensitivity to the selective b-adrenergic agonists dobutamine or terbutaline. The mean dose-response curves for each adrenergic agonist are demonstrated in Figure 2 . They are depicted as percent of the maximum lipolytic effect, which is preferable when half-maximum effects (namely sensitivity) are illustrated. In subjects with rapid weight loss, the dose response curve for noradrenaline was shifted to the left, while for clonidine, the dose response curve was shifted to the right as compared to the subjects with slow weight loss. The curves for dobutamine and terbutaline were almost superimposed in the two groups.
The importance of a 2 -adrenoceptor sensitivity for the outcome of VLCD treatment was examined using stepwise regression analysis. In this equation the rate of weight loss was entered as the dependent variable. As independent variable, beside pD 2 values for clonidine and noradrenaline; initial body weight, age, waist/hip ratio, plasma insulin and noradrenaline concentrations, basal and maximum isoprenaline stimulated lipolysis rate and adipocyte cellvolume were used. The pD 2 value for clonidine was the only signi®cant regressor with adjusted r 2 0.20, F 7.2. Accordingly about 20% of the variation in weight reduction could be explained by the a 2 -adrenoceptor sensitivity. The linear relationship between pD 2 values for clonidine and weight loss after four weeks on VLCD in the whole group is shown in Figure 3 (r 70.50, P 0.01).
There were no correlations between the sensitivity to noradrenaline and the sensitivity to selective agonists (data not shown).
Discussion
In this study, we found marked differences in adipocyte lipolysis regulation between obese women depending on the rate of weight loss during VLCD. Subjects with a more rapid weight loss during treatment differed in two ways in catecholamine induced lipolysis as compared to those with a slower rate of weight reduction. First, they showed 10-fold higher sensitivity to noradrenaline, shifting the mean doseresponse curve to the left, and secondly, they had an adrenoceptor subtype speci®c change, with a 10-fold decrease in the sensitivity to the antilipolytic effect induced by a 2 -adrenoceptor stimulation, shifting this dose-response curve to the right. A signi®cant correlation between the rate of weight loss and the sensitivity to the a 2 -adrenoceptor agonist clonidine was found.
There are several known predictors of successful weight management, among which the patients attendance to the program is very important.
14 Frustration or insuf®cient motivation due to slow initial weight loss has been related to early drop-out for females in VLCD programs. 15 During the current type of ambulatory treatment it is not always easy to ascertain full compliance. However, as far as we can judge from the results of the urine-ketone measurementsÐa reliable indicator of fasting/semi-fastingÐthe control of consumed VLCD packages and the weekly individual interviews, there was no evidence in the present study that differences in compliance could explain the variation in weight loss between the subjects.
Several factors are known that predict long-term maintenance of weight-loss after VLCD. In a recently published study, 24 h energy expenditure, fat oxidation, postprandial noradrenaline concentrations and The values are mean AE s.e.m. and represent lipolysis rates stimulated at maximum effective concentration with the basal rate subtracted. ADA is adenosine deaminase (1 U/ml). The values were compared using Student's t-test. ns, not signi®cant. The values are mean AE s.e. They were compared using Student's unpaired t-test. ns, not signi®cant.
plasma dihydrotestosterone levels could explain 41% of the variation in maximum weight loss in obese women after 36 weeks of hypo-caloric diet. 2 Exogenous factors are also of importance, namely continued intervention with follow-up programmes, psychological factors and the extent of physical activity. 3 However, measurements of metabolic factors at the adipocyte level are dif®cult to perform in the majority of obesity-treatment programs. Therefore little was previously known about the predictive value of variations in adipocyte metabolism for the rate of weight loss. We found, using stepwise regression analysis, that about 20% of the variation in short-term weight loss among all the obese subjects could be attributed to differences in a 2 -adrenoceptor sensitivity. It remains to be established whether this also holds true for long-term maintenance of the weight loss after returning to an isocaloric diet.
The increased noradrenaline sensitivity observed in the rapid weight losing group could not be explained by differences in sensitivity for the b-adrenoceptor subtype selective agents terbutaline and dobutamine, or by a post-receptor change (as judged by the results when lipolysis was stimulated with forskolin or dibutyryl cyclic AMP). However, the contemporaneous rightward shift of the dose-response curve for clonidine indicates a different balance between the stimulating b-adrenoceptors and inhibiting a 2 -adrenoceptors at submaximal noradrenaline concentrations, favouring the stimulatory component of the hormone in the rapid weight losing group. There was no correlation between the rate of weight loss and noradrenaline sensitivity. This could be due to the fact that noradrenaline acts on all adrenoceptors present in human fat cells whereas clonidine, a more selective drug, only acts on a 2 -adrenoceptors. This complex action of noradrenaline on all adrenoceptors may also explain the lack of correlation between noradrenaline sensitivity on the one hand, and the sensitivity to selective agonists, on the other hand.
Unfortunately, the amount of adipose tissue available in this study did not allow a more detailed examination of the molecular mechanisms behind the differences in a 2 -adrenoceptor sensitivity. In this respect, it should be mentioned that the adipocyte a 2 -adrenoceptors may mirror the presynaptic a 2 -adrenoceptors in the brain, involved in the regulation of energy expenditure. 17 It should be acknowledged that the possible in¯u-ence of b 3 -adrenoceptor function on the rate of weight loss was not evaluated in this study. This receptor is mainly expressed on a functional basis in visceral fat, 16 a region that for technical and ethical reasons could not be investigated in this type of study. However, subcutaneous adipose tissue is perhaps of greater interest in the present type of study, since it constituted the body's largest fat depot.
As always, caution must be taken when in vitro data are extrapolated to the in vivo situation. It is therefore dif®cult to judge the degree to which our present ®ndings of altered a 2 -adrenoceptor sensitivity in vitro may have an impact in vivo for the rate of weight loss. Validation of the lipolytic activity in situ using the microdialysis technique could be of interest in order to strengthen the results from the present study.
It is likely that the initial a 2 -adrenoceptor sensitivity, namely before VLCD, is a relevant predictor for weight loss. In a recent study by our group, 9 we found no difference in the a 2 -adrenoceptor function in obese women before as compared to during the fourth week of treatment with VLCD, indicating unchanged action of this receptor during long-term VLCD. In the present study, inhibition of lipolysis was investigated by the use of clonidine, a partial agonist at the human fat cell a 2 -adrenoceptors. An inhibition of basal lipolysis of about 80±85% was achieved. We have earlier found that UK 14304, which is known as a full agonist, inhibited lipolysis by about 60%. 9 This indicates that, in our incubation systems, UK 14304 may not be as effective an inhibitor of lipolysis as clonidine.
One clinical application for our ®ndings is the use of pharmacological treatment with a 2 -adrenoceptor antagonists. Therapeutic use of this kind of drug in the treatment of obesity has recently been reviewed. 17 Oral yohimbine administration (to date the only a 2 -adrenoceptor antagonist approved for use in human subjects) promoted an increment of plasma glycerol, NEFA and catecholamine concentrations. 18 The lipidmobilizing effect was however mainly attributed to increased lipolysis due to an increment in synaptic noradrenaline concentration, rather than via a blockade of the antilipolytic fat cell a 2 -adrenoceptors. Our data indicate that a 2 -adrenoceptor sensitivity in adipose tissue might be of importance for fat mobilization during VLCD. Therefore it is possible that a 2 -adrenoceptor antagonists with higher selectivity for adipose tissue could be of value in order to improve lipid mobilization and energy expenditure. This hypothesis needs of course to be tested clinically.
Conclusions
Obese women who subsequently show rapid weight loss during long-term VLCD are more sensitive in vitro to the lipolytic effect of noradrenaline because of decreased a 2 -adrenoceptor sensitivity as compared to women with slow weight loss. This suggests that adipose tissue a 2 -adrenoceptor sensitivity could be a metabolic predictor for weight loss during VLCD.
